Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. MDGL | 0.00 |
Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:
MDGL) with a Overweight rating and announces Price Target of $685.